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Abstract
Background: This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively
the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no
infliximab trough levels and/or detectable anti-infliximab levels.
Methods: Infliximab treated RA patients were included in this descriptive open-label cohort study. During one
infusioncycle (anti-)infliximab levels were assessed just before and one hour after infusion, and subsequently at
50%, 75% and at the end of the infusioncycle (pre-infusion).
Results: 27 patients were included. The median infliximab levels decreased from 77.0 mg/l (p25-p75: 65-89) one
hour after the infusion to pre-infusion levels of 0.0 mg/l (p25-p75: 0.0-3.1). In 7 (26%) patients pre-infusion anti-
infliximab antibodies were detected; these antibodies were already present halfway through the infusioncycle in 5
of the 7 individuals. Patients with detectable pre-infusion anti-infliximab antibodies have significantly more often
low/no infliximab levels (< 1 mg/l) halfway trough the infusioncycle (in 5/7 patients) compared to patients without
detectable pre-infusion anti-infliximab antibodies (0/20 patients, p < 0.001).
Conclusions: Most anti-infliximab forming patients have detectable anti-infliximab antibodies halfway through an
infusioncycle, which implies that these patients are exposed to nontherapeutical infliximab levels during more than
halve of their infusion cycle. As none of the patients without anti-infliximab antibodies had no/low-infliximab levels
halfway through the infusioncycle, the presence of pre-infusion anti-infliximab antibodies seems a sensitive and
specific predictor for no/low infliximab-levels
Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterised by inflammation of synovial tissue
leading to progressive articular cartilage and bone
destruction. To prevent progression of joint damage and
functional disability, early introduction of effective
disease modifying antirheumatic drugs (DMARDs) is
considered to be essential in the treatment of patients
with rheumatoid arthritis (RA). Besides traditional
DMARDS like methotrexate, tumour necrosis factor
(TNF) antagonists have been proven to reduce disease
activity, suppress radiographic joint damage and
decrease functional disability in patients with recent
onset [1,2] and established rheumatoid arthritis (RA)
[3,4]. About 40-60% and 20-40% of the patients met the
American College of Rheumatology (ACR) 50% and 70%
improvement criteria respectively [5], compared to pla-
cebo improvement percentages of 7-11% (ACR50) and
2-4% (ACR70).
However, these results also implicate that up to 60%
of patients with RA do not reach the clinical relevant
50% improvement. Therefore, non-responders (both pri-
mary as secondary non-responders) should be identified
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ease activity minimises chances of joint destruction [6].
Also treatment with TNF antagonist is associated with
considerable costs. Finally there is ongoing debate on
their safety and possible dose related adverse effects
[7,8].
Because valid prediction models are not available at
this point, close monitoring of individual disease activity
and adapting the treatment (dose) is the first available
step to improve the efficacy of RA-therapy [9,10].
Although disease activity guided treatment is a valuable
instrument, this strategy cannot distinguish between
patients who improve through the pharmacological
effect of infliximab or patients who’s improvement in
d i s e a s ea c t i v i t yi sc a u s e db yc o-medication, expectation
bias or more importantly the natural course of the dis-
ease (regression to the mean) [11].
Pharmacokinetic data with infliximab indeed show
that some patients achieve improvement and low disease
activity during therapy with infliximab, although this
response could most likely not be attributed to inflixi-
mab as these patients had no- or low-infliximab trough
levels. These reduced levels could partially be explained
by the formation of human antichimeric antibodies
(HACAs) which occurs in 8% to 43% of the RA patients
[12-14]. The formation of antibodies against infliximab
has been associated with altered infliximab pharmacoki-
netics and reduced serum infliximab concentrations
over time in patients with RA [12,13].
Clinically, it is relevant to know whether patients with
serum trough anti-infliximab antibodies also have these
antibodies present early in a treatment cycle or whether
they appear only at the end of a treatment cycle.
Patients with “early” anti-infliximab detectable antibody
formation would have a long window wit nontherapeuti-
cal levels of infliximab. The alternative scenario, appear-
ance of HACA’s predominately at the end of the
infusion cycle would be less important as adequate
infliximab levels would be present during the majority
of time between infusions. However, until now, it is
unknown what the relationship is between trough anti-
infliximab antibody levels and (anti-)infliximab antibody
throughout the treatment cycle.
This study therefore prospectively describes the course
of (anti)infliximab levels within an infusioncycle in
patients with rheumatoid arthritis in order to assess at
what moment patients develop low/no infliximab trough
levels and/or detectable anti-infliximab levels.
Methods
Patients
Patients with RA, according to the ACR 1987 revised
criteria, treated at the Sint Maartenskliniek (Nijmegen,
The Netherlands) for at least 3 months with 3 mg/kg
infliximab (irrespective of dose frequency) were included
in this observational, descriptive open-label pharmacoki-
netic cohort study. No other inclusion or exclusion cri-
teria were used. In the Sint Maartenskliniek all RA
patients receive 3 mg/kg infliximab, with dose intervals
adjusted to patient’s disease activity. Patients were trea-
ted according to the local disease activity guided proto-
col, When a patient does not reach low disease activity
o n3m g / k g / 4w k st h ep a t i e n ti ss w i t c h e dt oa n o t h e r
DMARD or biological.
Study protocol
Patients were enrolled between February and April 2008.
Ethical approval was obtained from the Ethics Commit-
tee Nijmegen-Arnhem and all participants gave written
informed consent before screening. A standardized chart
review form was used to collect data on demographics,
previous medication and clinical benefit of infliximab.
Pharmacokinetic and pharmacodynamic assessment
Serum samples for the measurement of (anti-)infliximab
levels were collected during one treatment cycle at five
time-points: one hour prior to the first infusion, one
hour after the infusion, at 50% and 75% of the infusion-
cycle, and just before the next infusion. The Disease
Activity Score (DAS28) was assessed at the same time
points excluding the time point just after the first infu-
sion (as this DAS-score is equal to the DAS-score prior
to the first infusion).
Infliximab- and anti-infliximab antibody levels in
serum were determined by an enzyme-linked immuno-
sorbent assay and a radioimmunoassay respectively
[13,15]. We categorized serum trough levels in low (< 1
mg/l), medium (1-5 mg/l) and high (> 5 mg/l) levels. In
contrast to the lower limit (1 mg/l), less information is
available about the maximum desirable infliximab serum
trough level. Therefore, we arbitrary choose that serum
trough levels above 5 mg/l are high levels, which is 5
times the minimum serum trough level and 3.3 times
the average serum trough level. Previously, Wolbink
et al [15] used tertiles to categorize serum levels at 14
weeks in low, medium and high levels, also categorizing
serum trough levels above 5 mg/l as high.
Statistical analysis
Descriptive statistics were provided using mean (+/- SD)
or median (p25-p75) values depending on the (non-)
parametric distribution of the variables. We used
Mantel-Haenszel x
2-tests to evaluate differences in pro-
portions, and Student’s t-tests to evaluate differences in
means. Non-parametric variables were analyzed using
the two-sample paired sign test. The threshold for sig-
nificance was set at p = 0.05. To test whether the rela-
tionship between the formation of anti-infliximab
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enced by confounders, the baseline variables of anti-
infliximab formers and non-formers were compared in a
univariate analysis and in a multivariate logistic associa-
tion model using the presence of no/low-infliximablevels
as dependent variable, antibody formation as central
determinant and all variables with a significant univari-
ate association with both the dependent and indepen-
dent variable of p < 0.1 as potential confounder.
Confounders were kept in the model when the beta for
the central determinant changed with > 10% after addi-
tion of the confounder
Results
Twenty-seven patients were enrolled in the study; their
demographic and clinical data at baseline are summar-
ized in table 1.
(Anti) Infliximab concentrations
Table 2 shows the median infliximab levels and the
decrease of infliximab serum trough levels during the
infusioncycle. In 7 (26%) patients anti-infliximab antibo-
dies were detected just prior to the next infusion. These
antibodies were already present at 50% of the infusion-
c y c l ei n5o ft h e7i n d i v i d u a l s. Infliximab serum levels
during a single infusioncycle categorized as patients with
and without detectable anti-infliximab antibodies are
depicted in figure 1 and 2. At 50% of the infusioncycle
5/7 (71% ± 33%) of the patients with HACAs just before
the next infusion had low infliximab serum levels (< 1
mg/l) which was significantly more frequent compared to
0/20 of the non-antibody forming patients (p < 0.001).
Anti-infliximab antibodies were significantly (p < 0.01)
more frequent in rheumatoid factor negative patients
(4 of 6 patients (67%)) compared to rheumatoid factor
positive patients (3 of 21 patients (14%)). Patients with
detectable antibodies were also significantly younger
(mean age: 53.5 (± 13.6) years) compared to patients
without detectable antibodies (mean age: 64.5 (± 6.7)
years; p < 0.01). Other baseline variables were not asso-
ciated with the formation of anti-infliximab antibodies.
C o n c o m i t a n tD M A R D sw e r eu s e di n6( 8 6 % )o ft h e
patients with detectable anti-infliximab antibodies and in
17 (85%) of patients without anti-infliximab antibodies
and remission or low disease activity was present in 4
(57%) of the patients with detectable anti-infliximab anti-
bodies compared to 9 (45%) patients without detectable
antibodies. A logistic regression association model showed
that age and the presence of rheumatoid factor did not act
as confounder on the relation between anti-infliximab
antibodies formation and infliximab serum trough levels.
Course of the disease activity between two infusions
Disease activity (DAS28) and EULAR-disease activity
classification percentages are shown in table 3. Disease
activity was significantly (p = 0.03) higher prior to the
next infusion than the disease activity halfway through
the infusion. At the end of the infusion interval
11 (41%) patients showed low disease activity or remis-
sion, which tended to be lower compared to the
16 (59%) patients with low disease activity or remission
halfway through the infusion interval (p = 0.06).
Discussion
Our results indicate that anti-infliximab antibodies are
frequently found in patients with low and moderate dis-
ease activity and that these antibodies are already
detectable in most of these patients halfway through an
infusioncycle. This implies that the presence of anti-
infliximab antibodies at the end of an infusioncycle
Table 1 Baseline characteristics of patients
n=2 7
Age (yrs) 61.6 ± 10.0
Woman (n,%) 15 (56)
Median disease duration (yrs, p25-p75) 11.2 (4.2- 17.4)
Median number of previous DMARDs (n) 2.5 (2.0- 3.3)
Previously treated with another biological (n, %) 3 (11%)
Rheumatoid factor positive (n,%) 21 (78)
Duration of infliximab therapy (yrs) 3.7 ± 2.3
Interval infliximab infusions (wks) 6.8 ± 2.0
Disease Activity at baseline
Remission (n,%) 7 (26)
Low disease activity (n,%) 6 (22)
Moderate disease activity (n,%) 11 (41)
High disease activity (n,%) 3 (11)
DMARD at baseline (n,%) 23 (85)
Methotrexate (n,%) 17 (63)
Dose (mg/week) 16.8 ± 5.5
Azathioprine (n,%) 4 (15%)
Prednisone at baseline (n, %) 5 (19%)
Dose (mg/day) 5.8 ± 1.8
Variables are expressed as mean ± SD unless stated otherwise.
wks = weeks; mths = months; yrs = years.












Median infliximab levels (p25-p75) 0.6 (0.0 - 3.1) 77.0 (65-89) 5.9 (1.5-13) 2.7 (0.2-5.7) 0.0 (0.0-3.1).
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throughout most of the infusioncycle.
The internal validity of our study appears to be ade-
quate. Although the number of patients in the present
study is limited, this does not necessarily hamper the
validity of this study as a higher number of patients
would only increase precision. Confounding was consid-
ered because the presence of rheumatoid factor was
related to both anti-infliximab formation and no/low
infliximab levels, however a multivariate regression
model could not demonstrate confounding.
The design of this study is not suitable to draw con-
clusions about the correlation between pharmacokinetic-
((anti)-infliximab levels) and the pharmacodynamic-
(disease activity) parameters. Patients were treated
according to the local disease activity guided protocol,
which automatically excluded the majority of non-
responders in this observational cohort. This could lead
to a selected study population, in which pharmacoki-
netic parameters could not be correlated with non-
response. Due to this selection bias, this study also can
not be used to assess possible risk factors for the forma-
tion of anti-infliximab antibodies.
Figure 1 Serum trough infliximab levels during the
infusioncycle in antibody-forming and non-anti-body forming
RA patients.
Figure 2 Distribution of infliximabserum trough levels and HACA-formation during the infusion interval.
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First, we found that in patients with low infliximab trough
levels, the presence of serum trough anti-infliximab anti-
bodies could be a specific and sensitive indicator for
absence of serum infliximab level during at least half of
the infusioncycle.
Secondly, our finding that one fifth of the patients
treated with infliximab have already non/low inflixi-
mab-levels halfway through the infusion suggests that
these patients do not benefit from infliximab at all.
One could argue that the effect of infliximab therapy
may be (partially) determined by peak levels or time
integrated AUC rather than by minimal inhibitory con-
centration (MIC), implying that measuring serum
trough levels is not indicative for clinical effect. This is
however not likely as subcutaneous anti-TNF agents
demonstrate similar efficacy without high peak serum
levels [16]. However, this issue can only be clarified in
an intervention study in which the dose of infliximab
is tapered down and stopped in patients with anti-
infliximab levels and/or suspected nontherapeutical
infliximab levels.
In this study, we found an increase in disease activity at
the end of the infusion interval. This could lead to an
underestimation of the effect of infliximab when disease
activity is only measured just before infusion. However,
previous research demonstrated that fluctuations in dis-
ease activity also importantly and independently contri-
bute to radiologic progression [17]. This implicates that
anti-rheumatic drugs should keep disease activity at a
stable, low level, and consequently keep structural damage
to a minimum. These finding also implicates that observa-
tional studies comparing subcutaneous- (etanercept adali-
mumab) and intravenous- (infliximab, abatacept and
tocilizumab) antirheumatic agents should be interpreted
with caution when disease activity for intravenous agents
is conveniently assessed at the end of an infusion interval
while disease activity in other drugs is often assessed on
different moments during a dosing interval.
Conclusion
This study demonstrates that a substantial proportion of
RA-patients treated with infliximab are already exposed
to no/low-infliximab levels during more than halve of
their infusion cycle. The presence of pre-infusion anti-
infliximab antibodies could be used as a sensitive and
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